TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3802930

Group type: EXPERIMENTAL
Intervention: Beclomethasone aerosol (BA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (Plc)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bronchodilator pretreatment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Increased dose oral steroid therapy
Number of subjects: 12
Study: 30790724

Group type: COMPARATOR
Intervention: Radiofrequency neurotomy (RN)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Endoscopic neurotomy (EN)
Number of subjects: 40
Study: 28531269

Group type: EXPERIMENTAL
Intervention: 25% caloric restriction (n = 145; 11.7% caloric restriction achieved on average)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Maintain current diet (n = 75)
Number of subjects: 220
Study: 24233256

Group type: EXPERIMENTAL
Intervention: Fiber-blend fortified enteral formula (FB, 15 g/L)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fiber-free formula (FF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Habitual diet
Number of subjects: 20
Study: 24521695

Group type: EXPERIMENTAL
Intervention: Nimotuzumab (200 mg doses, first 6 doses weekly, then every 21 days for up to 1 year)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Nimotuzumab in combination with radiotherapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Matched population treated with irradiation alone
Number of subjects: 35
Study: 22119456

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Progressive Strength Training (ST)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination Training (CT)
Number of subjects: 36
Study: 19949030

Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone (oMP) 1 g/day for 5 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (IV MP) 1 g/day for 5 days
Number of subjects: 40
Study: 17305736

Group type: EXPERIMENTAL
Intervention: Short-term topical steroid treatment (prednisolone acetate 1% eyedrops, stopped after 6 months)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Long-term topical steroid treatment (prednisolone acetate 1% eyedrops, continued once a day until 12 months postoperatively)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Comparison between short-term and long-term groups
Number of subjects: 305
Study: 15345740

Group type: EXPERIMENTAL
Intervention: Parkinsonism (defined as the presence of two or more categories of parkinsonian signs)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Gait impairment and bradykinesia
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Tremor and rigidity
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Coexistent moderate-to-severe cognitive impairment or stroke
Number of subjects: 455
Study: 11797069

Group type: EXPERIMENTAL
Intervention: 0.60 g/kg alcohol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.27 g/kg alcohol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9766764

Group type: EXPERIMENTAL
Intervention: Clonazepam (0.5 mg h.s. adjusted to two tablets by day 10 if needed)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/day for all patients initially and 40 mg/day if needed after 6 weeks)
Number of subjects: 80
Study: 7880577

Group type: EXPERIMENTAL
Intervention: Outpatient follow-up care
Number of subjects: 909

Group type: COMPARATOR
Intervention: General practice follow-up care
Number of subjects: 909
Study: 3068610

Group type: EXPERIMENTAL
Intervention: Broncho‐Vaxom (BV)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 1912206

Group type: EXPERIMENTAL
Intervention: Traditional method (TN) - negative approach warning of disease and death
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Positive treatment (TP) - positive reinforcement focused on quality of life
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group - without therapy
Number of subjects: 3
Study: 895528

Group type: EXPERIMENTAL
Intervention: Tryptophan (10 g orally administered)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31522843

Group type: COMPARATOR
Intervention: Standard shunt
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: Antibiotic-impregnated shunt (0.15% clindamycin and 0.054% rifampicin)
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: Silver shunt
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: Antibiotic-impregnated shunt
Number of subjects: 1605
Study: 27918333

Group type: EXPERIMENTAL
Intervention: Epidural Analgesia (EA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Continuous Surgical Site Analgesia (CSSA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Patient-Controlled Analgesic Morphine)
Number of subjects: 60
Study: 23579520

Group type: EXPERIMENTAL
Intervention: Transumbilical single-incision laparoscopic appendectomy (TSILA)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Classic 3-port laparoscopic appendectomy
Number of subjects: 84
Study: 20653608

Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR) exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control exercise
Number of subjects: 15
Study: 19808215

Group type: EXPERIMENTAL
Intervention: Weekly dosing (QW) of epoetin alfa
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Biweekly dosing (Q2W) of epoetin alfa
Number of subjects: 375

Group type: COMPARATOR
Intervention: Three times per week dosing (TIW) of epoetin alfa
Number of subjects: 375
Study: 16710858

Group type: EXPERIMENTAL
Intervention: Preoperative administration of 500 mg of methylprednisolone
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 76
Study: 15273831

Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 11316330

Group type: EXPERIMENTAL
Intervention: Melatonin secretion estimated by overnight urinary excretion of 6-sulphatoxymelatonin
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Birthweight and ponderal index at birth
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Duration of gestation
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Adult body mass index
Number of subjects: 159
Study: 9265122

Group type: EXPERIMENTAL
Intervention: Milligan‐Morgan operation
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Diathermy hemorrhoidectomy
Number of subjects: 135

Group type: COMPARATOR
Intervention: Closed hemorrhoidectomy (Ferguson and Khubchandani)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Milligan‐Morgan and diathermy hemorrhoidectomy without peduncle ligature
Number of subjects: 135
Study: 8205740

Group type: EXPERIMENTAL
Intervention: Penmix 10:90
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Penmix 20:80
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Penmix 30:70
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Penmix 40:60
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Penmix 50:50
Number of subjects: 17
Study: 2433932

Group type: EXPERIMENTAL
Intervention: Nimodipine 120 mg, started within 24 hours after onset of stroke, combined with standard treatment (hemodilution using low molecular dextran)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31211660

Group type: EXPERIMENTAL
Intervention: Second Step Child Protection Unit (CPU)
Number of subjects: 161
Study: 28902817

Group type: EXPERIMENTAL
Intervention: Electromyostimulation (EMS) of the crural muscles with the 'Veinoplus VI' unit (three 30-minute sessions a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control Group (comprehensive therapy including wearing a compression knee sock, phlebotrophic drugs, and dosed walking)
Number of subjects: 60
Study: 25780462

Group type: EXPERIMENTAL
Intervention: Doxapram (1 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 60
Study: 22841755

Group type: EXPERIMENTAL
Intervention: Power-related film clips
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Love stories
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control movie clips
Number of subjects: 17
Study: 21690512

Group type: EXPERIMENTAL
Intervention: 3-D educational computer model
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard written instruction (SWI)
Number of subjects: 100
Study: 18457589

Group type: EXPERIMENTAL
Intervention: Transmural collaborative care model including Problem Solving Treatment (PST), workplace intervention, antidepressant medication, and manual guided self-help.
Number of subjects: 126

Group type: COMPARATOR
Intervention: Care as usual (CAU).
Number of subjects: 126
Study: 17142415

Group type: EXPERIMENTAL
Intervention: Custom brace
Number of subjects: 10

Group type: COMPARATOR
Intervention: Off-the-shelf brace
Number of subjects: 10
Study: 12141721

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TAA) 220 microg, two sprays/nostril once daily AM
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 200 microg, two sprays/nostril once daily AM
Number of subjects: 352

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 352
Study: 10438709

Group type: EXPERIMENTAL
Intervention: SCF (20 micrograms/kg/d) combined with filgrastim (5 micrograms/kg/d)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Filgrastim alone (5 micrograms/kg/d)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: SCF plus filgrastim
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: SCF (20 micrograms/kg/d)
Number of subjects: 102
Study: 8867714

Group type: EXPERIMENTAL
Intervention: 10 mg adrenaline
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: 1 mg adrenaline
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 2277735

Group type: EXPERIMENTAL
Intervention: Chest physical therapy (PT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo visits
Number of subjects: 38
Study: 375171

Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 31739087

Group type: EXPERIMENTAL
Intervention: Early goal-directed therapy (EGDT)
Number of subjects: 1591

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1591
Study: 29236943

Group type: EXPERIMENTAL
Intervention: Induction TPF (Docetaxel 75 mg/m2 day 1; cisplatin 75 mg/m2 day 1; 5FU 750 mg/m2/day days 1-5) plus concomitant cisplatin-RT (40 mg/m2 weekly)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Concomitant cisplatin-RT alone
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Induction TPF plus concomitant cisplatin-RT
Number of subjects: 83
Study: 26200815

Group type: EXPERIMENTAL
Intervention: Local injection of methylcobalamin and lidocaine combination for 14 days (A1, B1)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Intramuscular methylcobalamin in addition to local lidocaine injection (A0, B0)
Number of subjects: 98
Study: 24919410

Group type: EXPERIMENTAL
Intervention: Travoprost/timolol BAK-free (TTFC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Latanoprost/timolol fixed combination (LTFC)
Number of subjects: 42
Study: 22532465

Group type: EXPERIMENTAL
Intervention: Rilpivirine (25 mg once daily)
Number of subjects: 1335

Group type: COMPARATOR
Intervention: Efavirenz (600 mg once daily)
Number of subjects: 1335

Group type: EXPERIMENTAL
Intervention: Rilpivirine
Number of subjects: 1335

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 1335
Study: 20216105

Group type: EXPERIMENTAL
Intervention: Nutrient enriched formula (A, n=56)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Term infant formula (B, n=57)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Nutrient enriched plus term formula (C, n=26)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Breast-fed preterm infants (D, n=25)
Number of subjects: 164
Study: 17559729

Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg/day
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/day
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study: 15613407

Group type: EXPERIMENTAL
Intervention: Recombinant methionyl human leptin (r‐metHuLeptin) administration
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Recombinant methionyl human leptin (r‐metHuLeptin) administration for 4 or 16 weeks
Number of subjects: 3
Study: 12401414

Group type: EXPERIMENTAL
Intervention: telephone follow-up
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: community resources utilization component
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: basic touchscreen computer-assisted dietary goal-setting intervention
Number of subjects: 320

Group type: COMPARATOR
Intervention: control condition without goal setting
Number of subjects: 320
Study: 10101627

Group type: EXPERIMENTAL
Intervention: Trimethaphan (TMP)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (TNG)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 28
Study: 7592204

Group type: EXPERIMENTAL
Intervention: Cold dry air inhalation and exhalation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Warm moist air inhalation and exhalation
Number of subjects: 10
Study: 2185723

Group type: EXPERIMENTAL
Intervention: Cysteamine eye drops
Number of subjects: 29
Study: 45059

Group type: EXPERIMENTAL
Intervention: 2.5 m² hollow-fibre dialyser
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.4 m² coil dialyser
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetate dialysate with high-efficiency dialyser
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bicarbonate as the source of base
Number of subjects: 0
Study: 31622954

Group type: EXPERIMENTAL
Intervention: Self‐Assessment of Sleep Survey (SASS)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Self‐Assessment of Sleep Survey - Split (SASS‐Y)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 131
Study: 28569619

Group type: EXPERIMENTAL
Intervention: Point massage of liver and stomach channel
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Pith and trotter soup
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Massage + soup
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (routine nursing)
Number of subjects: 320
Study: 27608978

Group type: EXPERIMENTAL
Intervention: Integrated neonatal survival kit and early stimulation package delivered by community health workers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current standard of care
Number of subjects: 0
Study: 25134497

Group type: EXPERIMENTAL
Intervention: Automatic Self Transcending Meditation (ASTM) plus Treatment as Usual (TAU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone
Number of subjects: 0
Study: 22390410

Group type: EXPERIMENTAL
Intervention: Major Depressive Syndrome (MDS)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Anxiety Syndrome (AS)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Situationally based self‐efficacy
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Expectancies of controlling negative affect by means other than smoking
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Dimensions of primary and secondary tobacco dependence
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Self‐efficacy in negative/affective situations
Number of subjects: 251
Study: 19670975

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both surgical methods
Number of subjects: 24
Study: 17443369

Group type: EXPERIMENTAL
Intervention: Group visits
Number of subjects: 186

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 186
Study: 15996356

Group type: EXPERIMENTAL
Intervention: One-stage surgery (group A)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Two-stage surgery (group B) - Control group
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: One-piece implants (group C)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Early loading (group D)
Number of subjects: 108
Study: 11953624

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy focused on the calcified area (4000 impulses, 0.78 mJ/mm2, 2 sessions)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Extracorporeal shock wave therapy focused on the origin of the supraspinatus tendon (4000 impulses, 0.78 mJ/mm2, 2 sessions)
Number of subjects: 50
Study: 9861127

Group type: EXPERIMENTAL
Intervention: Granisetron 20 micrograms kg‐1
Number of subjects: 160
Study: 1993631

Group type: EXPERIMENTAL
Intervention: Misonidazole 1 g/m2 with 3.0 Gy x 10 fractions
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Misonidazole 2 g/m2 with 5.0 Gy x 6 fractions
Number of subjects: 859

Group type: COMPARATOR
Intervention: 3.0 Gy x 10 fractions without Misonidazole
Number of subjects: 859

Group type: COMPARATOR
Intervention: 5.0 Gy x 6 fractions without Misonidazole
Number of subjects: 859
Study: 6524276

Group type: EXPERIMENTAL
Intervention: Bolus injection of 60 ml mepivacaine 1% with adrenaline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fractional injections of 30 + 30 ml mepivacaine 1% with adrenaline (20 min interval)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (Bolus and Fractional injections)
Number of subjects: 60
Study: 31048271

Group type: EXPERIMENTAL
Intervention: Pharmacist implemented educational treatment programme
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 154
Study: 29027034

Group type: EXPERIMENTAL
Intervention: Low-intensity LED therapy (λ 640 ± 20 nm, 6 J/cm2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (PG)
Number of subjects: 40
Study: 27392872

Group type: EXPERIMENTAL
Intervention: Remote monitoring using wearable sensors in conjunction with standard care
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Remote monitoring using wearable sensors
Number of subjects: 40
Study: 24619865

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) consumption (75 mg EGCG)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 24
Study: 22578104

Group type: EXPERIMENTAL
Intervention: Physical activity monitoring and distance counseling (n=264)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Control group (n=257)
Number of subjects: 521
Study: 19889063

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 484
Study: 18974808

Group type: EXPERIMENTAL
Intervention: Library and informatics training with emphasis on PubMed searching skills
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (identical training two weeks later)
Number of subjects: 60
Study: 16482375

Group type: EXPERIMENTAL
Intervention: Telemedicine management service for diabetes patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 0
Study: 14557561

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (5 g/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 10823096

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg i.v.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline 2 ml i.v. (Control)
Number of subjects: 90
Study: 9063788

Group type: EXPERIMENTAL
Intervention: Dermagraft-TC (DG-TC)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Cryopreserved human cadaver skin (allograft)
Number of subjects: 66
Study: 8363321

Group type: EXPERIMENTAL
Intervention: Triangular rehabilitation (n = 13)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Rectangular rehabilitation (n = 13)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Both groups (triangular and rectangular)
Number of subjects: 26
Study: 3783868

Group type: EXPERIMENTAL
Intervention: Fructose diet (21% of energy as fructose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sucrose diet (23% of energy as sucrose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Starch diet (almost all carbohydrate energy as starch)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fructose diet
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sucrose diet
Number of subjects: 24
Study: 31553815

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for targeted therapy-related fatigue (CBT-TTF)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 44
Study: 28669554

Group type: EXPERIMENTAL
Intervention: Double-check group
Number of subjects: 86

Group type: COMPARATOR
Intervention: Single-check group
Number of subjects: 86
Study: 27380540

Group type: EXPERIMENTAL
Intervention: Siponimod 10 mg
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Siponimod 2 mg
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Siponimod 1.25 mg
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Siponimod 0.5 mg
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Siponimod 0.25 mg
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 24920292

Group type: EXPERIMENTAL
Intervention: Maximal workload (VO2 max)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Relative workload (70% of VO2 max/10 min)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Absolute workload (75W/10 min)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Pre-exercise
Number of subjects: 39
Study: 22409920

Group type: EXPERIMENTAL
Intervention: Manual acupuncture intervention at acupoints Quchi (LI11) or Tianquan (PC2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 20356491

Group type: EXPERIMENTAL
Intervention: Single-agent gemcitabine (1000 mg/m² at Days 1 and 8 for a 21-day cycle)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin (gemcitabine 1000 mg/m² at Days 1 and 8 and carboplatin AUC5 at Day 2 for a 21-day cycle)
Number of subjects: 68
Study: 18565577

Group type: EXPERIMENTAL
Intervention: Online cessation intervention with $10 weekly incentives and personalized smoking cessation messages.
Number of subjects: 517

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 517